ASCO FRAMEWORK AND ESMO-MCBS IN THE INCORPORATION OF NEW TECHNOLOGIES: CASE STUDY AND CHALLENGES IN THE PRIVATE HEALTH CARE SYSTEM

HTA60

Sales R, Silva BC, Laloni MT, Ferreira CG, Aguiar Jr PN Oncoclínicas&Co/MedSir, Belo Horizonte, MG, Brazil, Oncoclínicas&Co/MedSir, São Paulo, SP, Brazil rahyssa.sales@oncoclinicas.com

OBJECTIVES

The rapid development of antineoplastic technologies, combined with a trend of studies with early endpoints, underscores the need for robust, evidence-based decision-making strategies.

This study aims to evaluate the utility and limitations of these tools in integrating new technologies in the institutional protocol of the largest private healthcare Oncology Network in Brazil.



two-years

CLINIC BENEFIT SCALES

RESULTS

PHASE III TRIALS:

HIGH RISK OF BIAS: OVERALL SURVIVAL AS PRIMARY ENDPOINT: 89% 70% 40%

> **MAGNITUDE OF BENEFIT +** LOW RISK OF BIAS 100%

CONCLUSIONS

• The low rate of studies scoring high grade at both clinical benefit frameworks highlights significant concerns and illustrates the challenges of incorporating new technologies.

• The disparity in results is driving us to develop new



tools to ensure confidence in data interpretation

